Zoetis Inc. (NYSE:ZTS) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP lifted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 632.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 138,239 shares of the company's stock after purchasing an additional 119,372 shares during the quarter. Two Sigma Investments LP's holdings in Zoetis were worth $22,523,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. Callahan Advisors LLC increased its holdings in Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after buying an additional 6,221 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after acquiring an additional 46,050 shares during the period. Schroder Investment Management Group increased its stake in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares in the last quarter. Vanguard Group Inc. raised its holdings in Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after purchasing an additional 120,158 shares during the last quarter. Finally, Alberta Investment Management Corp raised its holdings in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock worth $4,904,000 after purchasing an additional 28,700 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ZTS shares. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler boosted their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus dropped their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of "Buy" and an average price target of $212.75.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is owned by company insiders.

Zoetis Stock Performance

NYSE ZTS opened at $161.33 on Thursday. The business's 50-day moving average price is $156.58 and its 200 day moving average price is $165.05. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a market capitalization of $71.82 billion, a PE ratio of 29.49, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the company earned $1.38 earnings per share. The company's quarterly revenue was up 1.4% on a year-over-year basis. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.